Publications from JLSG

1. Cerebellar ataxia in pediatric patients with Langerhans cell histiocytosis.
Imashuku S, Ishida S, Koike K, Ichikawa M, Minato T, Suzuki Y, Kobayashi R, Morimoto A; Japan LCH Study Group.
J Pediatr Hematol Oncol. 2004 Nov;26(11):735-9.

2. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K, Tsunematu Y, Fujimoto J, Imashuku S.
Pediatr Blood Cancer. 2006 Aug;47(2):194-9.

3. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study.
Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M, Fujimoto J, Bessho F, Horibe K, Tsunematsu Y, Imashuku S; Japan Langerhans Cell Histiocytosis Study Group.
Cancer. 2006 Aug 1;107(3):613-9.

4. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy.
Imashuku S, Okazaki NA, Nakayama M, Fujita N, Fukuyama T, Koike K, Minato T, Kobayashi R, Morimoto A; Japan LCH Study Group.
Pediatr Blood Cancer. 2008 Feb;50(2):308-11.

5. Impact of reactivation on the sequelae of multi-system Langerhans cell histiocytosis patients.
Morimoto A, Kobayashi R, Maeda M, Asami K, Bessho F, Imashuku S; Japan LCH Study Group.
Pediatr Blood Cancer. 2008 Apr;50(4):931-2.

6. Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis. Report from the Japan LCH Study Group.
Imashuku S, Shioda Y, Kobayashi R, Hosoi G, Fujino H, Seto S, Wakita H, Oka A, Okazaki N, Fujita N, Minato T, Koike K, Tsunematsu Y, Morimoto A; Japan LCH Study Group (JLSG).

Haematologica. 2008 Apr;93(4):615-8.